SUMMARY: Researchers will study a new antibody’s effectiveness against H5N1 avian influenza as a step toward a new treatment for cats affected by this serious disease.
THE PROBLEM: H5N1 avian influenza is an emerging threat for cats in the United States. While the virus primarily infects birds, it can also infect mammals, including domestic and wild cats, where mortality rates can reach 70%. Cats can be exposed through contact with infected birds, raw foods, or contaminated environments. Currently, no approved treatments exist, and supportive care or off-label antivirals offer limited effectiveness and carry potential risks, leaving a critical unmet need for safe and effective therapeutic options in feline populations.
THE PROJECT: The team proposes to develop CM-PW4, a new antibody treatment for cats infected with H5N1. CM-PW4 is based on a human antibody, CM-PW3, that the team developed to fight influenza in people. To make it safe and effective in cats, they will create a “feline-compatible” version by combining the virus-targeting part of CM-PW3 with components from the cat immune system. This design preserves the antibody’s ability to recognize the virus while preventing immune reactions in cats.
The team will produce CM-PW4 and test its purity, stability, and ability to bind H5N1. They’ll then assess its effectiveness in feline cells infected with the virus, measuring how well it blocks infection. They will also test its stability in feline serum to ensure it can survive in the body long enough to provide protection. The team has extensive experience in developing antibody therapies for viral infections. While there are potential challenges, they have strategies to address them, including adjusting the antibody design or using alternative antibodies if needed.CM-PW4 addresses a critical need in veterinary medicine.
POTENTIAL IMPACT: By preventing death from H5N1, this therapy could protect cats, support their caregivers, and reduce the risk of influenza spreading between animals and even potentially humans.